tradingkey.logo

Roche Provides Safety Update On Elevidys™ Gene Therapy For Duchenne Muscular Dystrophy In Non-Ambulatory Patients

ReutersJun 15, 2025 5:25 AM

- Roche Holding AG ROG.S:

  • [AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR] ROCHE PROVIDES SAFETY UPDATE ON ELEVIDYS™ GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY IN NON-AMBULATORY PATIENTS

  • ROCHE HOLDING AG - PAUSES DOSING OF ELEVIDYS IN NON-AMBULATORY PATIENTS

  • ROCHE HOLDING AG - WORKING WITH HEALTH AUTHORITIES TO MODIFY PATIENT CARE

  • ROCHE HOLDING AG - DECISION FOLLOWS TWO CASES OF FATAL ACUTE LIVER FAILURE IN NON-AMBULATORY PATIENTS

  • ROCHE HOLDING AG - NEW DOSING RESTRICTIONS DO NOT IMPACT AMBULATORY DMD PATIENTS

  • ROCHE HOLDING AG - EUROPEAN REGULATORS REQUEST TEMPORARY CLINICAL HOLDS ON ELEVIDYS STUDIES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI